(Q45052983)

English

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

scientific article published on 23 April 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Clostridium difficile

0 references

author name string

Jing-Hui Tian

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Steven R Fuhrmann

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Stefanie Kluepfel-Stahl

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Robert J Carman

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Larry Ellingsworth

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

David C Flyer

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

23 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

4249-4258

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Epidemiology of nosocomial clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Clostridium difficile toxins: mechanism of action and role in disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Comparative sequence analysis of the Clostridium difficile toxins A and B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Treatment with monoclonal antibodies against Clostridium difficile toxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Toxin B is essential for virulence of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Both, toxin A and toxin B, are important in Clostridium difficile infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Molecular characterization of the Clostridium difficile toxin A gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.04.045

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45052983&oldid=2063989421"